PTC Therapeutics, Inc. PTCT shares are trading lower by $1.40 (10 percent) at $11.78 in Thursday's session.
The catalyst for the decline is the announcement that the company's drug trial for ACT CF has missed primary and secondary endpoints. Now the company plans to discontinue current clinical development of Ataluren in CF close ongoing extension studies and withdraw marketing application authorization in Europe.
After a lower open, it continued in that direction until it bottomed at $10.25 and began to rebound. That marks the lowest level for the issue since it bottomed on November 11 at $9.75. So far, the ensuing rally took the issue to $12.05, but has fallen into the $11.00 handle.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.